Berenberg Sees 25% Upside in Eli Lilly as Obesity Drugs Keep Winning

Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.